DocumentsDate added
ORIGINAL ARTICLE
S. Naveen1*,B. N. Lenka2,Alin Kumar Nayak1
1 Third Year PG Student, Department of General Surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
2 Assistant Professor, Department of General Surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to
*Dr S. Naveen, Third Year PG Student,Department of General Surgery,Hi-Tech Medical College and Hospital,Bhubaneshwar, Odisha, India
Article citation: Naveen S, Lenka BN,Nayak AK. A clinical study of secondary haemorrhoids and its management. J Pharm Biomed Sci 2016;06(03): 238–240. Available at www.jpbms.info
ABSTRACT
Background Haemorrhoids are defined as the symptomatic enlargement and distal displacement of the normal anal cushions. The most common symptom of haemorrhoids is rectal bleeding associated with bowel movement. The abnormal dilatation and distortion of the vascular channel, together with destructive changes in the supporting connective tissue within the anal cushion, is a paramount finding of haemorrhoids. In most instances, haemorrhoids are treated conservatively using many methods such as lifestyle modification, fibre supplement, suppository, anti-inflammatory drugs and administration of venotonic drugs. Non-operative approaches include sclerotherapy and rubber band ligation. An operation is indicated when non-operative approaches have failed or complications have occurred. Several surgical approaches for treating haemorrhoids have been introduced including haemorrhoidectomy and stapled haemorrhoidopexy.
Materials and Methods Clinical study of secondary haemorrhoids and its management were collected from cases admitted in Hi-Tech Medical College and Hospital, Bhubaneswar,
Odisha, during the period from 1st January 2014 to 31st December 2015.
Results The study was conducted on 50 cases who were admitted in Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha with features of secondary haemorrhoids.
Conclusions In this study, we assess the common causes of secondary haemorrhoids and its management.
KEYWORDS secondary haemorrhoids, haemorrhoidal plexus, banding, haemorrhoidectomy (closed and stapled), bowel care, sitz bath
REFERENCES
1.Loder PB, Kamm MA, Nichold RJ, Philips RK. Hemorrhoids:pathology,pathophysiology and aetiology. Br J Surg. 1994;81:946–954.
2.Aigner F, Gruber H, Conrad F, Eder J, Wedel T, Zelger B, et al.Revised morphology and hemodynamics of the anorectal vascular plexus: impact on the course of hemorrhoidal disease. Int J Colorectal Dis. 2009;24:105–113.
3.Goldberg SM, Santhat N, David AR. Colon, rectum and anus in Schwartz principles of surgery, 6th ed. New York: Mchraw Hill;1994. p. 1192.
4.Thomson WH. The nature of haemorrhoids. Br J Surg. 1975;62(7):542–552.
5.Thaha MA, Campbell KL, Steele RJC. Non-operative treatment for haemorrhoidal disease. Cochrane Database Syst Rev. 2004;2.
6.MacRae HM, McLeod RS. Comparison of hemorrhoidal treatment modalities: a meta-analysis. Dis Colon Rectum. 1995;38:687–694.
7.Parks AG. The surgical treatment of hemorrhoids. Br J surg.1956;43:337–351.
8.Murie JA, Sim AJ, Mackenzie I. The importance of pain, pruritis and soiling as symptoms of hemorrhoids and their response to hemorrhoidectomy or rubber band ligation. Br J Surg. 1981;68:247–249.
9.Alonso-Coello P, Guyatt G, Heels-Ansdell D, Johanson JF, Lopez-Yarto M, Mills E, et al. Laxatives and topical treatments for hemorrhoids.Cochrane Database Syst Rev. 2005;2.
10.Harari D, Sarkarati M, Gurwitz JH, McGlinchey-Berroth G, Minaker KL. Constipation-related symptoms and bowel programme concerning individuals with spinal cord injury. Spinal Cord.1997;35:394–401.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript. The first two authors contributed equally to the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Original article
Chongwei Chen1, Guohua Cheng2*
1 Candidate for degree of master in Clinical Pharmacy, School of Pharmacy, Jinan University, 601 Huangpu Avenue West,Guangzhou, China, P.C. 510632
2 Professor, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, China, P.C. 510632
Address reprint requests to
*Guohua Cheng,
Jinan University, 601 Huangpu Avenue West, Guangzhou,China, P.C. 510632
Article citation: Chen C, Cheng G. Nedaplatin plus docetaxel in the treatment of advanced oesophageal cancer: a retrospective study in China. J Pharm Biomed Sci 2016;06(03):255–258.Available at www.jpbms.info
ABSTRACT
Background Currently, there is no standard chemotherapy for advanced oesophageal cancer, especially for those with recurrent or metastatic one.
Objective To retrospectively investigate the efficacy and safety of combination of nedaplatin with docetaxel in the treatment of Chinese patients with advanced oesophageal cancer.
Methods Patients with advanced oesophageal cancer from two specialist hospitals in Guangzhou received intravenously 60 mg/m2 docetaxel for 1 h, followed by 80 mg/m2 nedaplatin for 2 h, on day 1 for every 28 days. Cycles continued until documented disease progression, unacceptable toxicity or patient’s refusal. Kaplan–Meier analysis was used to estimate survival time.
Results Between 2008 and 2013, 368 patients were enrolled into the study. A total of 26 patients achieved complete response and 170 patients achieved partial response. The
median of progression-free survival and overall survival were 4.4 months and 8.8 months, respectively. The non-hematological toxicities were generally mild to moderate; severe hematological toxicities included neutropenia and anaemia, which observed in 85 (23.1%) patients and 112 (30.4%) patients; thrombocytopenia was mild (mostly Grade1); there were no febrile neutropenia and treatment-related death.
Conclusions The combination regimen of nedaplatin with docetaxel is effective and safe.
Keywords chemotherapy, docetaxel, oesophageal cancer, nedaplatin, retrospective study
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.